D01799Z
Brachytherapy Peripheral Nerve to None with Iodine 125 (I-125), High Dose Rate (HDR) Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | D Radiation Therapy |
| Body System | 0 Central and Peripheral Nervous System |
| Operation | 1 Brachytherapy |
| Body Part | 7 Peripheral Nerve |
| Approach | 9 High Dose Rate (HDR) |
| Device | 9 Iodine 125 (I-125) |
| Qualifier | Z None |
Procedure Overview
Brachytherapy of the central and peripheral nervous system is a radiation treatment in which a radioactive source is placed directly into or next to nervous system tissue, most often within the cavity left after a brain tumor is surgically removed. Rather than aiming beams through the skull from an external machine, this approach delivers radiation from a source positioned at very close range, allowing a concentrated dose to the tissue at highest risk of tumor recurrence while limiting exposure to the rest of the brain.
It is used selectively, often for certain malignant brain tumors where the surgical team places catheters or radioactive seeds at the time of tumor resection, or in a planned procedure shortly afterward. The therapy may involve a temporary source removed after the treatment period or, less commonly, permanently implanted material that decays over time.
Anatomy & Axis Detail
Peripheral Nerve
When brachytherapy targets a peripheral nerve, sources are typically placed intraoperatively into the tumor bed following resection of a nerve sheath tumor or a soft tissue sarcoma abutting a major nerve trunk, delivering dose to the tissue plane around the nerve to reduce local recurrence while limiting exposure to nearby skin, muscle, and vasculature. Because peripheral nerves run through soft tissue rather than a protective bony canal, source placement must account for the nerve's mobility and its relationship to adjacent structures that were disturbed during surgery. Functional nerve preservation is a central concern, so the specific nerve or plexus segment treated should be documented clearly, distinguishing this application from brachytherapy delivered to the brain, brain stem, or spinal cord.
Modality Qualifier: High Dose Rate (HDR)
High Dose Rate (HDR) identifies brachytherapy delivered with a radioactive source of high activity, allowing treatment to be completed in minutes per fraction, often on an outpatient basis with afterloading applicators. It contrasts with Low Dose Rate (LDR), which uses a weaker source left in place for hours to days, trading a longer treatment time for a different radiobiological effect and staffing exposure profile.
Isotope: Iodine 125 (I-125)
Iodine-125 is a low-energy, low-dose-rate radioisotope most often loaded into small permanent seeds implanted directly into tissue, commonly for early-stage prostate cancer or ocular tumors via plaque brachytherapy. Its longer half-life (about 60 days) gives a slower, more protracted dose delivery than Pd-103 or Cs-131, which is the key distinction among the permanent-seed isotopes.
Coding & Documentation
Coding requires documentation that a radioactive source was physically placed within or adjacent to nervous system tissue, along with whether the source was intended as a temporary placement to be removed later or a permanent implant, since this determines the qualifier. The operative report should identify the specific nervous system structure treated and the isotope or device used to deliver the dose.
A frequent error is coding the catheter or applicator placement itself as the therapy code when the radioactive source has not yet been loaded, since some brachytherapy is delivered in a staged fashion with the source inserted afterward in a separate procedure. Coders should also make sure the resection of the tumor, if performed in the same session, is captured with a separate procedure code rather than folded into the radiation code.
Commonly Confused With
This family is commonly confused with Beam Radiation of the nervous system, since both treat the same body system with therapeutic radiation; the difference is that brachytherapy places the source directly at the treatment site rather than delivering radiation from an external machine. It is also sometimes confused with the surgical placement of a drug-delivery wafer or other implant during tumor resection, which is coded as a device implantation rather than radiation therapy unless the material itself is radioactive.